Search results
Tematy dnia
22 gru 2021 · Remdesivir improves clinical outcomes in patients hospitalized with moderate-to-severe coronavirus disease 2019 (Covid-19). Whether the use of remdesivir in symptomatic, nonhospitalized patients...
- Correspondence Mar 17, 2022 Outpatient Remdesivir to Prevent Progression to Severe Covid-19
Gottlieb RL, Vaca CE, Paredes R, et al. Early remdesivir to...
- Free Full Text
We conducted a double-blind, randomized, placebo-controlled...
- Editorial Jan 27, 2022 The Goldilocks Time for Remdesivir — Is Any Indication Just Right E.L. Heil and S. Kottilil
Remdesivir, a nucleotide analogue prodrug that inhibits the...
- Original Article Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma H. Tilly and Others
Diffuse large B-cell lymphoma (DLBCL) is typically treated...
- Original Article Cardiovascular and Cancer Risk With Tofacitinib in Rheumatoid Arthritis S.R. Ytterberg and Others
Increases in lipid levels and cancers with tofacitinib...
- Interactive Medical Case Up in The Air J.V. Loewenthal and Others
This interactive case features a 58-year-old man who reports...
- Correspondence Mar 17, 2022 Outpatient Remdesivir to Prevent Progression to Severe Covid-19
22 kwi 2022 · Today, WHO made a strong recommendation for nirmatrelvir and ritonavir, sold under the name Paxlovid, for mild and moderate COVID-19 patients at highest risk of hospital admission, calling it the best therapeutic choice for high-risk patients to date.
7 lut 2022 · Federal agencies now recommend remdesivir as one of four options for treating early COVID-19. These medicines, when started within five to 10 days of the onset of symptoms, could help patients...
22 maj 2020 · We conducted a double-blind, randomized, placebo-controlled trial of intravenous remdesivir in adults who were hospitalized with Covid-19 and had evidence of lower respiratory tract infection.
20 paź 2020 · Remdesivir is an antiviral medication that targets a range of viruses, including SARS-CoV-2, the coronavirus that causes COVID-19. A final report of a randomized, controlled trial showed that remdesivir sped up recovery, improved mortality and reduced respiratory support for hospitalized patients.
25 cze 2020 · Remdesivir is the first medicine against COVID-19 to be recommended for authorisation in the EU. Data on remdesivir were assessed in an exceptionally short timeframe through a rolling review procedure, an approach used by EMA during public health emergencies to assess data as they become available.
Today, FDA approved Veklury (remdesivir), the first drug approved to treat COVID-19, for use in adults and pediatric patients 12 years of age and older and weighing at least 40 kg (about 88...
